TSE:1820
TSE:1820Construction

Nishimatsu Construction (TSE:1820): Valuation Insights Following Updated FY26 Guidance and Real Estate Profit Boost

Nishimatsu Construction (TSE:1820) updated its earnings guidance for the year ending March 2026, revealing lower expected net sales because of overseas project delays. At the same time, improved profits from its real estate business are boosting the overall profit outlook. See our latest analysis for Nishimatsu Construction. After a generally steady run this year, Nishimatsu Construction’s latest guidance revision has injected some energy into the share price. The stock climbed 2.55% in the...
TSE:4528
TSE:4528Pharmaceuticals

Ono Pharmaceutical (TSE:4528) Valuation Spotlight as PRISM BioLab Collaboration Achieves Drug Discovery Milestone

Ono Pharmaceutical (TSE:4528) and PRISM BioLab have reached a key milestone in their oncology research collaboration. PRISM received a milestone payment as their joint efforts, using PRISM's PepMetics platform, advanced potential clinical candidates. See our latest analysis for Ono Pharmaceutical. Ono Pharmaceutical’s collaboration success comes after several expansion moves, including opening a new European office, as investor optimism continues to build. The stock’s share price has surged...
TSE:6856
TSE:6856Electronic

Is Strong Earnings and a Higher Dividend Altering the Investment Case for HORIBA (TSE:6856)?

HORIBA, Ltd. reported a 6.7% increase in net sales and a 21% rise in net income attributable to shareholders for the nine months ending September 30, 2025, while also forecasting a higher dividend payout for the full year. This combination of strong financial results and a raised dividend forecast highlights management’s confidence in the company’s ongoing performance and outlook. With net income and dividends on the rise, we’ll explore how these trends may shape HORIBA’s long-term...